Some of the contents of this website cannot be promoted in the USA (including its territories and possessions) for regulatory reasons.

Please choose your country/geographic area:

International

USA **including its territories and possessions

Genitourinary Syndrome of Menopause

RenovaLase® treatment reduces the symptoms of Genitourinary Syndrome of Menopause (GSM) in Breast Cancer Survivors

Authors: M. Gambacciani, M. Levancini

Published in Ital Jounal Gynaecol Obstet. 2015;27(1):15-17





1. IMPORTANT PILOT STUDY IN A SPECIFIC PATIENT POPULATION

The genitourinary syndrome of menopause (or vulvovaginal atrophy) affects almost half of all postmenopausal women. Because local hormone replacement therapy is contraindicated in women with a history of estrogen-dependent tumors, till now there was no single agent which could ameliorate the quality of life for this patients.

2. MATERIALS AND METHODS

13 postmenopausal women with the presence of GSM and a history of treated breast cancer were treated with Erbium gynecological laser (Fotona, Slovenia). Patients received 3 laser sessions, each 30 days apart. Subjective symptoms (vaginal dryness and dyspareunia) were assessed using a visual analogue scale (VAS) and Vaginal Health Index Score (VHIS) was calculated.

3. RENOVALASE® TREATMENT INDUCES SIGNIFICANT IMPROVEMENT OF GSM

Vaginal dryness and dyspareunia scores were progressively decreased following RenovaLase® treatment. The results were maintained at all follow-ups.
Vaginal Health Index Score (VHIS) was significantly increased after treatment and the results were maintained at all follow-ups. There were no adverse events reported.

4. RENOVALASE® IS EFFECTIVE AND SAFE TREATMENT OF GSM IN POSTMENOPAUSAL BREAST CANCER SURVIVORS

Significant reduction of GSM symptoms in breast cancer survivors is a revolutionary step-up in improving the long-term quality of life of this group of women. More studies in specific post-cancer patients are needed to fully assess the potential of RenovaLase® in specific groups of cancer survivors.

 

Read article

Back

Find More Knowledge On:

Join Us on Social Networks

Download Fotona Mobile Application

All information published in this website is of general nature and only has an informative purpose. Under no circumstances can it replace any treatment or therapy prescribed by a physician or other healthcare professional. Any information on medical procedures and treatments in this website are intended for informative purposes only and do not provide the knowledge required for their application.

All Fotona medical lasers are CE marked and cleared for sale in the EU. For countries where specific national approvals or clearances are required (for example by the FDA in the United States), some of the products and/or applications may not have been cleared yet. Similarly, local patents may limit usage for certain technologies and applications. Please check with Fotona, your local Fotona distributor or your national regulatory body to find out whether a specific product or application is available for sale and use in your country.

Fotona 2023 ©